|Bid||5.69 x 2900|
|Ask||6.95 x 2900|
|Day's Range||6.27 - 6.48|
|52 Week Range||4.05 - 8.05|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.88|
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Cerus Corporation announced today that its fourth quarter and full-year 2018 results will be released on Tuesday, February 26, 2019, after the close of the stock market.
In 2011 Obi Greenman was appointed CEO of Cerus Corporation (NASDAQ:CERS). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Read More...
Cerus Corporation (CERS) today announced unaudited preliminary product revenue for the fourth quarter and full year 2018 and provided 2019 product revenue guidance. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2018 totaled $16.5 million compared to $16.2 million during the same period the prior year. Based on the fourth quarter unaudited preliminary product revenue, the Company expects full year 2018 product revenue to be $60.9 million, ahead of the top end of the range of the Company’s most recent guidance of $58 million to $60 million.
Mr. Moore joins Cerus from Quest Diagnostics, where he served as Vice President, Lab Operations and was previously the Senior Vice President of Operations, Biomedical Services at the American Red Cross, the world’s largest blood center operation.
Cerus Corporation (CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, non-inferiority, Phase 3 study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures. The first patient was enrolled at Houston Methodist Hospital in Houston, Texas. “We are pleased to have started enrollment in ReCePI, our pivotal Phase 3 study,” said Dr. Richard Benjamin, Cerus’ chief medical officer.
Cerus Corporation (CERS) today announced that it has filed for CE Mark registration for the Company’s INTERCEPT red blood cell (RBC) system. “The INTERCEPT RBC CE Mark submission is a major milestone in the Company’s history and represents the culmination of years of effort to complete the full INTERCEPT portfolio of products to help ensure that patients have access to safe blood transfusions,” said William ‘Obi’ Greenman, the Company’s president and chief executive officer. “Red blood cell transfusions are one of the most common hospital procedures globally, and there are more than 25 million red blood cell units transfused in Europe, Middle East and Africa (EMEA) annually.
Does Cerus Corporation (NASDAQ:CERS) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]
While small-cap stocks, such as Cerus Corporation (NASDAQ:CERS) with its market cap of US$750m, are popular for their explosive growth, investors should also be aware of their balance sheet to Read More...
Cerus Corporation (CERS) announced today that the American Red Cross has received approval by the U.S. Food and Drug Administration (FDA) for their first biologics license application (BLA) for interstate distribution of platelets that have been pathogen-reduced with INTERCEPT Blood Systems. “This BLA approval is a key milestone for Cerus and the American Red Cross,” said Vivek Jayaraman, Cerus’ chief commercial officer.
Cerus Corporation announced today the issuance of a new U.S. Food and Drug Administration draft guidance document on bacterial risk control strategies for platelet collection and transfusion.
If you’re interested in Cerus Corporation (NASDAQ:CERS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
Cerus Corporation announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Vivek Jayaraman, Cerus’ chief commercial officer, are scheduled to present a corporate update at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum at 1:30 p.m.
Cerus Corporation announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin Green, Cerus’ vice president, finance and chief financial officer, are scheduled to present a corporate update at the 2018 Stephens NY Investment Conference at 9:45 a.m.
On a per-share basis, the Concord, California-based company said it had a loss of 11 cents. The biomedical products company posted revenue of $15.4 million in the period. Cerus expects full-year revenue ...
Cerus Corporation (CERS) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s pathogen-reduced cryoprecipitate product candidate. The basis of the designation is improved treatment of massive hemorrhage, a life-threatening medical condition. "The proposed label indication for pathogen-reduced cryoprecipitate would be to control massive bleeding associated with fibrinogen deficiency,” said Dr. Laurence Corash, Cerus’ chief scientific officer.
Cerus Corporation announced today that its third quarter results will be released on Thursday, November 1, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 P.M.
Cerus Corporation (CERS) is presenting its strategic roadmap and outlining its multi-year growth strategy at the 2018 Cerus Institutional Investor Meeting today in Boston. “Our efforts to establish the INTERCEPT Blood System as the standard of care for transfused blood components globally continue to gain traction,” commented William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “Our preliminary Q3 product revenue of $15.4 million underscores the strong market demand for the INTERCEPT Blood System during the quarter, especially in the U.S. Given our preliminary Q3 results, we are raising our full year product revenue guidance from a range of $56 million to $58 million to our new range of $58 million to $60 million, representing an increase of 33% to 38% compared to 2017 product revenue,” continued Greenman.
Cerus Corporation announced today its schedule of key events and presentations at the 2018 AABB Annual Meeting which is taking place in Boston on October 13 through October 16.
Cerus Corporation (CERS) today announced Dr. Laurence Corash, the Company’s co-founder and chief scientific officer has been awarded the prestigious Dale A. Smith Memorial Award by AABB’s National Blood Foundation. The award, which was created in 2002, honors Dale A. Smith, a long-time Baxter Health executive who was responsible for establishing the Fenwal Division. The award is presented to individuals or organizations in recognition of groundbreaking work in utilizing technology for innovation in transfusion medicine or cellular therapies.